Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221180 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02221180: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT02221180 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02221180, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the bioequivalence of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with the metformin IR tablet co-administered with canagliflozin in healthy fed and fasted participants.
Primary Outcome
Plasma concentrations of metformin are used to evaluate how much metformin is in the blood over time.
Interventions
- DRUG Metformin
- DRUG Canagliflozin
- DRUG Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
What the finished NCT02221180 record still lists
NCT02221180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT02221180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02221180 about?
NCT02221180 is a clinical study titled "Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants". The purpose of this study is to evaluate the bioequivalence of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with the metformin IR tablet co-administered with canagliflozin in healthy fed and fasted participants.
What is the current status of trial NCT02221180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-08. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02221180?
The interventions under investigation include: Metformin (DRUG), Canagliflozin (DRUG), Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC] (DRUG).
Who is sponsoring clinical trial NCT02221180?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02221180's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia